Insmed Incorporated Common Stock INSM
i
Market dataready · fetched 2026-11-12T04:07:29.573Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:32:43.835550345Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T04:07:29.139913+00:00
Insmed Incorporated Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 128.48 | 50.2% | 8.4% | 112.16 | 48.7% | 7.0% |
| 25Δ | 126.61 | 49.1% | 7.1% | 114.27 | 44.2% | 5.4% |
| 30Δ | 124.83 | 48.2% | 5.9% | 115.67 | 42.0% | 4.5% |
| 35Δ | 123.62 | 49.0% | 5.3% | 116.71 | 41.0% | 3.9% |
| 40Δ | 122.42 | 49.7% | 4.7% | 117.74 | 40.0% | 3.4% |
| 45Δ | 121.21 | 50.5% | 4.1% | 118.77 | 38.9% | 2.8% |
| 50Δ | 120.00 | 51.2% | 3.5% | 119.80 | 37.9% | 2.2% |
| 55Δ | 118.53 | 55.2% | 3.2% | 120.77 | 37.5% | 1.9% |
| 60Δ | 117.05 | 59.1% | 2.9% | 121.72 | 37.2% | 1.6% |
| 65Δ | 115.58 | 63.1% | 2.5% | 122.67 | 36.9% | 1.3% |
| 70Δ | 113.58 | 67.8% | 2.2% | 123.62 | 36.6% | 1.0% |
| 75Δ | 111.26 | 73.1% | 1.9% | 124.58 | 36.3% | 0.8% |
| 80Δ | 108.72 | 76.7% | 1.5% | |||
20Δ
- Pseudo strike
- 128.48
- IV
- 50.2%
- B/E move
- 8.4%
- Pseudo strike
- 112.16
- IV
- 48.7%
- B/E move
- 7.0%
25Δ
- Pseudo strike
- 126.61
- IV
- 49.1%
- B/E move
- 7.1%
- Pseudo strike
- 114.27
- IV
- 44.2%
- B/E move
- 5.4%
30Δ
- Pseudo strike
- 124.83
- IV
- 48.2%
- B/E move
- 5.9%
- Pseudo strike
- 115.67
- IV
- 42.0%
- B/E move
- 4.5%
35Δ
- Pseudo strike
- 123.62
- IV
- 49.0%
- B/E move
- 5.3%
- Pseudo strike
- 116.71
- IV
- 41.0%
- B/E move
- 3.9%
40Δ
- Pseudo strike
- 122.42
- IV
- 49.7%
- B/E move
- 4.7%
- Pseudo strike
- 117.74
- IV
- 40.0%
- B/E move
- 3.4%
45Δ
- Pseudo strike
- 121.21
- IV
- 50.5%
- B/E move
- 4.1%
- Pseudo strike
- 118.77
- IV
- 38.9%
- B/E move
- 2.8%
50Δ
- Pseudo strike
- 120.00
- IV
- 51.2%
- B/E move
- 3.5%
- Pseudo strike
- 119.80
- IV
- 37.9%
- B/E move
- 2.2%
55Δ
- Pseudo strike
- 118.53
- IV
- 55.2%
- B/E move
- 3.2%
- Pseudo strike
- 120.77
- IV
- 37.5%
- B/E move
- 1.9%
60Δ
- Pseudo strike
- 117.05
- IV
- 59.1%
- B/E move
- 2.9%
- Pseudo strike
- 121.72
- IV
- 37.2%
- B/E move
- 1.6%
65Δ
- Pseudo strike
- 115.58
- IV
- 63.1%
- B/E move
- 2.5%
- Pseudo strike
- 122.67
- IV
- 36.9%
- B/E move
- 1.3%
70Δ
- Pseudo strike
- 113.58
- IV
- 67.8%
- B/E move
- 2.2%
- Pseudo strike
- 123.62
- IV
- 36.6%
- B/E move
- 1.0%
75Δ
- Pseudo strike
- 111.26
- IV
- 73.1%
- B/E move
- 1.9%
- Pseudo strike
- 124.58
- IV
- 36.3%
- B/E move
- 0.8%
80Δ
- Pseudo strike
- 108.72
- IV
- 76.7%
- B/E move
- 1.5%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 43.13% | |
| 44.22% | |
| 46.77% | |
| 45.32% | |
| 44.70% | |
| 52.57% | |
| 43.45% | |
| 44.67% | |
| 42.52% | |
| 41.68% | |
| 41.53% | |
| 42.33% | |
| 42.85% | |
| 41.57% | |
| 42.24% | |
| 42.20% | |
| 42.91% | |
| 45.24% | |
| 46.83% | |
| 46.49% | |
| 46.92% | |
| 46.55% | |
| 47.54% | |
| 54.03% | |
| 55.54% | |
| 49.67% | |
| 50.02% | |
| 50.02% | |
| 50.66% | |
| 52.80% | |
| 52.43% | |
| 52.97% | |
| 51.18% | |
| 52.84% | |
| 53.89% | |
| 55.12% | |
| 55.83% | |
| 59.39% | |
| 59.55% | |
| 58.19% | |
| 58.03% | |
| 59.04% | |
| 61.10% | |
| 61.48% | |
| 68.07% | |
| 58.95% | |
| 58.47% | |
| 59.01% | |
| 58.56% | |
| 58.40% | |
| 57.94% | |
| 59.65% | |
| 61.69% | |
| 67.81% | |
| 48.17% | |
| 44.37% |
Biotechnology
INVA
Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
More →IONS
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapies in the United States. The company is headquartered in Carlsbad, California.
More →IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's…
More →IPSC
Century Therapeutics Inc. (Ticker: IPSC) is a leading biotechnology company specializing in allogenic cell therapy, with a transformative approach to cancer treatment. Leveraging…
More →IRD
Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision. Utilizing cutting-edge…
More →IRON
Description unavailable
More →